Start with its own history
At 31.43×, RDY is 14.4% above its 10-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
NYSE · RDYDrug Manufacturers - Specialty & GenericUpdated Nov 4, 2026
Dr. Reddy's Laboratories Limited P/E ratio
Current valuation, historical context, and peer comparisons.
Current P/E ratio
31.43×
14.4% abovethe 10-year annual average
Share price14.77
÷Earnings per share0.47
Price and EPS in quote currency. Calculation details
Investors are paying 31.43 for every 1 of reported earnings per share.
P/E over time
2017 – 2026
Annual P/ESelected-period average 27.47×
3-year average20.03×3 positive annual observations
5-year average21.48×5 positive annual observations
10-year average27.47×10 positive annual observations
Peer median · TTM28.71×6 peers with positive P/E
Historical P/E ratios
Annual period-end data · 25 observations
| Period end | P/E | Change |
|---|---|---|
| Mar 31, 2026 | 24.38× | +43.4% |
| Mar 31, 2025 | 17.00× | -9.2% |
| Mar 31, 2024 | 18.71× | +9.6% |
| Mar 31, 2023 | 17.07× | -43.5% |
| Mar 31, 2022 | 30.23× | -30.4% |
| Mar 31, 2021 | 43.44× | +63.8% |
| Mar 31, 2020 | 26.53× | +7.3% |
| Mar 31, 2019 | 24.71× | -31.6% |
View all 25 annual observations +
| Period end | P/E | Change |
|---|---|---|
| Mar 31, 2018 | 36.14× | -1.0% |
| Mar 31, 2017 | 36.51× | +40.7% |
| Mar 31, 2016 | 25.94× | -3.5% |
| Mar 31, 2015 | 26.89× | +36.1% |
| Mar 31, 2014 | 19.76× | +434.4% |
| Mar 31, 2013 | 3.70× | -11.8% |
| Mar 31, 2012 | 4.19× | -16.5% |
| Mar 31, 2011 | 5.02× | -87.5% |
| Mar 31, 2010 | 40.28× | N/M |
| Mar 31, 2009 | N/M | N/M |
| Mar 31, 2008 | 5.17× | +107.4% |
| Mar 31, 2007 | 2.49× | -81.4% |
| Mar 31, 2006 | 13.36× | -75.1% |
| Mar 31, 2005 | 53.57× | +768.0% |
| Mar 31, 2004 | 6.17× | +55.2% |
| Mar 31, 2003 | 3.98× | +17.3% |
| Mar 31, 2002 | 3.39× | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
How RDY compares
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
 RDY This stockDr. Reddy's Laboratories Limited | 31.43× |
 VTRSViatris Inc. | N/M |
 AMRXAmneal Pharmaceuticals, Inc. | 46.40× |
 TEVATeva Pharmaceutical Industries Limited | 93.00× |
 BHCBausch Health Companies Inc. | N/M |
 AMPHAmphastar Pharmaceuticals, Inc. | 16.10× |
 ANIPANI Pharmaceuticals, Inc. | 14.83× |
 HLNHaleon plc | 18.61× |
 SUNPHARMA.NSSun Pharmaceutical Industries Limited | 38.81× |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
What does RDY’s P/E tell you?
Compare like with like
The median of the 6 positive peer ratios above is 28.71×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
Check what drives earnings
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Take RDY into your spreadsheet
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore WisesheetsQuarterly P/E · latest quarterLQ selects the latest reported quarter. Requires the Wisesheets add-in. See available data
=WISE("RDY", "PE Ratio", "LQ")Sources & calculation methodology
Current P/E
Share price 14.77 ÷ EPS 0.47 = 31.43×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Nov 4, 2026; this is not a real-time trading quote.
History & averages
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
Data definitions and limitations
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
RDY P/E ratio: common questions
The essentials behind the numbers.
Dr. Reddy's Laboratories Limited's current P/E is 31.43× based on the quote data last updated Nov 4, 2026. It represents the share price divided by reported earnings per share. Prices and earnings may refresh on different schedules.
Annual P/E uses earnings for a completed fiscal year. Trailing-12-month (TTM) P/E uses the latest four quarters, while forward P/E uses forecast earnings. These are not interchangeable. This page labels peer ratios as TTM and shows dated annual or quarterly historical observations; it does not show forward estimates.
N/M means not meaningful: the feed has no positive P/E for that observation. Negative or zero earnings should not be ranked as a low positive valuation multiple. N/M observations are excluded from the averages shown above.
Divide the share price by earnings per share (EPS). For example, a share price of 100 and EPS of 5 gives a P/E of 20×. This page uses the price and EPS supplied together in the quote when both are positive.
Price timestamps, EPS definitions, share classes, adjustments, and fiscal periods can differ. A forward P/E also uses forecast earnings rather than reported earnings. Compare the inputs and as-of dates before comparing two displayed ratios.
Not necessarily. The average describes previous market pricing, not fair value. Changes in earnings quality, growth expectations, debt, accounting, and business risk can justify a different multiple today.